The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium–glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheeler, David C, Stefansson, Bergur V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z I, Chertow, Glenn M, Douthat, Walter, Dwyer, Jamie P, Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B, McMurray, John J V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D, Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C David, Langkilde, Anna Maria, Heerspink, Hiddo J L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538235/
https://www.ncbi.nlm.nih.gov/pubmed/32862232
http://dx.doi.org/10.1093/ndt/gfaa234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538235/
https://www.ncbi.nlm.nih.gov/pubmed/32862232
http://dx.doi.org/10.1093/ndt/gfaa234

Ejemplares similares